Zoetis Inc. (ZTS) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Zoetis Inc. is a global leader in animal health, operating in two geographic segments: the United States and International. The company markets products for companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, fish, sheep). A significant accounting change occurred effective January 1, 2026, aligning the fiscal year-end of international subsidiaries to December 31, eliminating a previous one-month reporting lag. Prior period data has been recast to reflect this change.
Key Financial Metrics
| Metric (in millions, except per share) | Q2 2026 | Q2 2025 (Recast) | YTD 2026 | YTD 2025 (Recast) |
|---|---|---|---|---|
| Revenue | $2,468 | $2,474 | $4,730 | $4,672 |
| Net Income | $691 | $726 | $1,292 | $1,328 |
| Diluted EPS | $1.65 | $1.63 | $3.08 | $2.97 |
| Operating Cash Flow (YTD) | $1,056 (vs. $1,120 YTD 2025) | |||
| Long-Term Debt | $9,048 (Net of discount/costs) | |||
| Cash & Equivalents | $1,476 (as of June 30, 2026) | |||
| Effective Tax Rate | 20.2% | 20.4% | 20.4% | 21.2% |
Material Changes vs. Prior Period
- Revenue: Q2 2026 revenue was flat (-0.2%) compared to Q2 2025. On an operational basis (excluding foreign exchange), revenue declined 2% due to volume decreases in key companion animal franchises and the impact of a prior divestiture. Foreign exchange provided a favorable impact of approximately 2%.
- Net Income: Net income decreased 5% in Q2 2026, driven by higher restructuring charges ($77 million vs. $30 million in Q2 2025) and increased interest expense. Adjusted Net Income (non-GAAP) decreased slightly by 1% to $781 million.
- Segment Performance:
- U.S. Segment: Revenue declined 7% (operational -7%) due to softer demand in companion animal products (dermatology, Simparica Trio) and generic competition. Livestock revenue grew 23% driven by cattle products.
- International Segment: Revenue increased 8% (operational +5%), driven by growth in parasiticides, diagnostics, and livestock products. Foreign exchange contributed a 3% favorable impact.
- Restructuring: Significant increase in restructuring charges to $77 million in Q2 2026, primarily due to employee termination costs under a comprehensive cost and productivity program.
Guidance, Outlook, and Risks
- Outlook: Management continues to monitor global macroeconomic conditions, tariffs, and trade protection measures. The company expects operational revenue to remain under pressure from competitive dynamics and price sensitivity in the U.S. companion animal market.
- Capital Allocation: The company remains committed to its $6 billion share repurchase program, with $1.3 billion remaining as of June 30, 2026. In Q2 2026, the company repurchased approximately 6.2 million shares. Dividends declared were $0.530 per share.
- Acquisitions: Zoetis entered into an agreement to acquire Neogen Corporation's animal genomics business, expected to close in the second half of 2026.
- Risks & Contingencies:
- Legal Proceedings: A securities class action was filed in May 2026 alleging false statements regarding product safety and market share. Related shareholder derivative actions were also filed. The company intends to defend vigorously.
- Tax Audit: The IRS has proposed an additional tax liability of approximately $450 million related to the 2018 tax return. The company disagrees with the position and is appealing.
- Market Risks: Exposure to foreign exchange rates (46% of revenue in foreign currencies), interest rate fluctuations, and potential disease outbreaks affecting livestock demand.
Key Facts for Investor Verification
- Operational Revenue Decline: Verify the sustainability of the 2-3% operational volume decline in key U.S. companion animal franchises (dermatology, parasiticides) amidst generic competition.
- Restructuring Costs: Assess the total expected cost of the comprehensive cost and productivity program, given the significant increase in Q2 charges ($77 million).
- Legal Exposure: Monitor the status of the May 2026 securities class action and the IRS audit regarding the $450 million proposed tax liability.
- Debt Structure: Review the impact of the $2.0 billion convertible senior notes issued in late 2025 on future dilution and interest expense.
- FX Sensitivity: Evaluate the company's hedging strategy given that nearly half of revenue is denominated in foreign currencies, which provided a 2% tailwind in Q2.